Qiming's US Fund Leads $25 Million Round for Boston's ZappRx

Qiming US Healthcare Fund led a $25 million Series B funding in ZappRx, a Boston company offering an automated specialty drug prescribing service. China's Qiming announced the $125 million US fund in January of this year. ZappRx said its platform is currently being used in several US academic medical centers and large multi-specialty practices. The specialty drug market, which involves ordering several products for combination regimens, is expected to reach $400 billion by 2020, according to ZappRx. More details.... Share this with colleagues: // //